Intact Investment Management Inc. Lowers Holdings in IQVIA Holdings Inc. $IQV

Intact Investment Management Inc. trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 57.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,200 shares of the medical research company’s stock after selling 3,000 shares during the period. Intact Investment Management Inc.’s holdings in IQVIA were worth $418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Root Financial Partners LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $43,000. Asset Dedication LLC increased its holdings in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in shares of IQVIA in the second quarter worth about $39,000. J.Safra Asset Management Corp boosted its stake in shares of IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares in the last quarter. Finally, Hemington Wealth Management grew its position in shares of IQVIA by 43.4% during the 3rd quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 79 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IQV shares. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. Mizuho set a $266.00 price objective on shares of IQVIA in a report on Friday, January 9th. BMO Capital Markets assumed coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price on the stock. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Trading Up 1.7%

Shares of IQVIA stock opened at $239.28 on Tuesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The stock’s 50 day simple moving average is $229.57 and its 200-day simple moving average is $206.73. The stock has a market cap of $40.75 billion, a P/E ratio of 32.82, a P/E/G ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.